Seres Therapeutics (MCRB) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update
November 10, 2016 7:30 AM EST
- Analyses of SER-109 Phase 2 results on track for completion by year
end;
Company intends to discuss proposed future SER-109
clinical development plans with the FDA -
- Pipeline progress with SER-287 and SER-262 Phase 1b study execution;
data
read-outs continue to be expected in 2017 -
- New microbiome patent strengthens the Companys intellectual property estate -
- Conference call at 8:00 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More
